JP2019513015A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513015A5
JP2019513015A5 JP2018547941A JP2018547941A JP2019513015A5 JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5 JP 2018547941 A JP2018547941 A JP 2018547941A JP 2018547941 A JP2018547941 A JP 2018547941A JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547941A
Other languages
English (en)
Japanese (ja)
Other versions
JP6987072B2 (ja
JP2019513015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021958 external-priority patent/WO2017156488A2/en
Publication of JP2019513015A publication Critical patent/JP2019513015A/ja
Publication of JP2019513015A5 publication Critical patent/JP2019513015A5/ja
Priority to JP2021194152A priority Critical patent/JP7469284B2/ja
Application granted granted Critical
Publication of JP6987072B2 publication Critical patent/JP6987072B2/ja
Priority to JP2023198762A priority patent/JP7755634B2/ja
Priority to JP2025167026A priority patent/JP2026004489A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547941A 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用 Active JP6987072B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021194152A JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306354P 2016-03-10 2016-03-10
US62/306,354 2016-03-10
PCT/US2017/021958 WO2017156488A2 (en) 2016-03-10 2017-03-10 Activin type 2 receptor binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194152A Division JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2019513015A JP2019513015A (ja) 2019-05-23
JP2019513015A5 true JP2019513015A5 (enExample) 2020-04-23
JP6987072B2 JP6987072B2 (ja) 2021-12-22

Family

ID=59790844

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018547941A Active JP6987072B2 (ja) 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A Pending JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A Pending JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Country Status (19)

Country Link
US (4) US10307455B2 (enExample)
EP (2) EP3426680B1 (enExample)
JP (4) JP6987072B2 (enExample)
KR (4) KR102457751B1 (enExample)
CN (2) CN116284392A (enExample)
AU (1) AU2017230091B2 (enExample)
BR (1) BR112018067813A2 (enExample)
CA (1) CA3015277A1 (enExample)
DK (1) DK3426680T3 (enExample)
ES (1) ES2987504T3 (enExample)
FI (1) FI3426680T3 (enExample)
HR (1) HRP20241557T1 (enExample)
HU (1) HUE069467T2 (enExample)
LT (1) LT3426680T (enExample)
PL (1) PL3426680T3 (enExample)
PT (1) PT3426680T (enExample)
RS (1) RS66251B1 (enExample)
SI (1) SI3426680T1 (enExample)
WO (1) WO2017156488A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
CA3142149A1 (en) 2019-05-30 2020-12-03 Acceleron Pharma, Inc. Actrii-binding proteins and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20230174620A1 (en) * 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US20230391880A1 (en) * 2020-11-11 2023-12-07 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
CA3200465A1 (en) * 2020-11-30 2022-06-02 Xiwu HUI Anti-cldn18.2 antibody, drug conjugate, and preparation method therefor and use thereof
JP2024511315A (ja) * 2021-03-10 2024-03-13 アクセルロン ファーマ インコーポレイテッド Actrii-alk4アンタゴニスト及び心不全の治療方法
WO2022261436A2 (en) * 2021-06-11 2022-12-15 Acceleron Pharma Inc. Actrii proteins and uses thereof
EP4577301A1 (en) 2022-08-26 2025-07-02 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
IL326224A (en) 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2026080757A2 (en) * 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies
CN122404555A (zh) * 2025-01-17 2026-07-17 沈阳三生制药有限责任公司 结合acvr2a和/或acvr2b的抗体及其制备与应用
WO2026158505A1 (zh) * 2025-01-24 2026-07-30 信立泰(成都)生物技术有限公司 一种抗acvr2a抗体或其抗原结合片段及用途
EP4785960A1 (en) 2025-01-31 2026-08-05 SixPeaks Bio AG Glp-1 antibody conjugates

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
EP0866805A1 (en) * 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE69736247T2 (de) 1996-05-20 2007-05-24 Novozymes A/S Verfahren zur herstellung von proteinhydrolysate
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU750453B2 (en) 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005116052A2 (en) 2004-04-27 2005-12-08 Research Development Foundation ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
US8008074B2 (en) 2006-03-20 2011-08-30 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ActRIIa拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
MX2009008510A (es) * 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
PE20150680A1 (es) 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
ITAN20090010U1 (it) 2009-04-27 2010-10-28 Arnaldo Sorci Staffa di bloccaggio protettiva
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
EP3202459B1 (en) 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
KR20180023028A (ko) 2009-11-05 2018-03-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 에칭된 미러들을 구비하는 반극성 {20-21} ⅲ-족 질화물 레이저 다이오드들
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
KR20130048242A (ko) * 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
CA2817008A1 (en) * 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
TW201249867A (en) * 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
JP6472999B2 (ja) * 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
WO2013008185A1 (en) * 2011-07-14 2013-01-17 Pfizer Inc. Treatment with anti-pcsk9 antibodies
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
US9029510B2 (en) * 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
JP2015525230A (ja) * 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
JP6049767B2 (ja) 2013-02-01 2016-12-21 株式会社ブリリアントサービス 栽培システム、栽培プログラム、および栽培方法
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
MX2017007519A (es) 2014-12-08 2017-08-22 Novartis Ag Antagonistas de miostatina o activina para el tratamiento de sarcopenia.
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2024026159A5 (enExample)
AU2021200348B2 (en) Binding molecules with modified J-chain
JP2022534966A5 (enExample)
CN109311971B (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
TWI767174B (zh) 異二聚免疫球蛋白
KR101852915B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
CN115605594A (zh) 抗igf-1受体人源化抗体
TWI815305B (zh) Pd-1/vegf四價雙特異性抗體、其製備方法和用途
CA3064298A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2019515676A5 (enExample)
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
KR20230141817A (ko) 이중특이 항체
JP2021500895A5 (enExample)
WO2019080909A1 (en) TARGETING THERAPEUTIC ANTIBODY RANKL
JP2022534514A5 (enExample)
CN113166239B (zh) 抗il-17a抗体及其应用
TW202535947A (zh) CD33抗體、CD33/Vδ2多特異性抗體及其用途
CN115811987A (zh) 抗神经酰胺抗体
CN121399157A (zh) 淋巴毒素β受体激动剂结合蛋白
AU2023291634C9 (en) Follistatin fusion proteins
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
HK1212719B (en) Fully human anti-rankl antibody
BR122025021892A2 (pt) Células hospedeiras